Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from infliximab to adalimumab in Crohn's disease remission
2006-006632-22Phase 4Completed
- Sponsor
- KU Leuven
- Start
- Dec 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in Crohn's disease comparing Maintenance infliximab with Switch to adalimumab (2 arms). Primary endpoint: Clinical remission at week 54. Started Dec 2006; status: completed.
02
Drugs
adalimumabinfliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2006-006632-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006632-22.